MA31388B1 - Utilisation d'un composé i pour prévenir ou traiter une formation de biofilm - Google Patents

Utilisation d'un composé i pour prévenir ou traiter une formation de biofilm

Info

Publication number
MA31388B1
MA31388B1 MA32359A MA32359A MA31388B1 MA 31388 B1 MA31388 B1 MA 31388B1 MA 32359 A MA32359 A MA 32359A MA 32359 A MA32359 A MA 32359A MA 31388 B1 MA31388 B1 MA 31388B1
Authority
MA
Morocco
Prior art keywords
compound
biofilm formation
preventing
treating biofilm
treating
Prior art date
Application number
MA32359A
Other languages
Arabic (ar)
English (en)
Inventor
David Reid
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38534753&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31388(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA31388B1 publication Critical patent/MA31388B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention porte sur l'utilisation d'un composé de formule (i), de préférence l'acide 4-[3,5-bis(2-hydroxyphényle)-[l,2,4]triazol-l-yl]benzoïque ou un sel pharmaceutiquement acceptable de celui-ci, pour la préparation d'un médicament destiné à être utilisé dans le traitement de la formation d'un biofilm, par exemple, p. Aeruginosa, par exemple chez des patients atteints de fibrose kystique.
MA32359A 2007-05-22 2009-11-20 Utilisation d'un composé i pour prévenir ou traiter une formation de biofilm MA31388B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07108650A EP1994930A1 (fr) 2007-05-22 2007-05-22 Compositions de triazole pour traiter la formation de biofilm
PCT/EP2008/056231 WO2008142094A1 (fr) 2007-05-22 2008-05-21 Utilisation d'un composé i pour prévenir ou traiter une formation de biofilm

Publications (1)

Publication Number Publication Date
MA31388B1 true MA31388B1 (fr) 2010-05-03

Family

ID=38534753

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32359A MA31388B1 (fr) 2007-05-22 2009-11-20 Utilisation d'un composé i pour prévenir ou traiter une formation de biofilm

Country Status (18)

Country Link
US (2) US8309590B2 (fr)
EP (3) EP1994930A1 (fr)
JP (1) JP5470245B2 (fr)
KR (1) KR101519675B1 (fr)
CN (2) CN103381271A (fr)
AU (1) AU2008252964B2 (fr)
BR (1) BRPI0811103A2 (fr)
CA (1) CA2685112A1 (fr)
CL (1) CL2008001469A1 (fr)
IL (1) IL201832A (fr)
MA (1) MA31388B1 (fr)
MX (1) MX2009012628A (fr)
NZ (1) NZ580735A (fr)
RU (1) RU2478385C2 (fr)
TN (1) TN2009000487A1 (fr)
TW (1) TWI419690B (fr)
WO (1) WO2008142094A1 (fr)
ZA (1) ZA200907415B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8829198B2 (en) 2007-10-31 2014-09-09 Proteotech Inc Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
US20090227647A1 (en) 2008-03-05 2009-09-10 Thomas Lake Compounds, Compositions and Methods for the Treatment of Islet Amyloid Polypeptide (IAPP) Accumulation in Diabetes
GB2463181B (en) 2007-05-14 2013-03-27 Univ New York State Res Found Induction of a physiological dispersion response in bacterial cells in a biofilm
EP1994930A1 (fr) * 2007-05-22 2008-11-26 Novartis AG Compositions de triazole pour traiter la formation de biofilm
GB201021186D0 (en) * 2010-12-14 2011-01-26 Novabiotics Ltd Composition
TWI415572B (zh) 2011-06-17 2013-11-21 Univ Chang Gung 利用１，２，３，４，６－五－ｏ－沒食子醯基－ｄ－葡哌喃糖來抑制生物膜形成
US10028933B2 (en) * 2015-07-22 2018-07-24 Ohio State Innovation Foundation Compositions and methods for inhibiting the growth of multi-drug resistant microbes
RU2646488C2 (ru) * 2016-04-25 2018-03-05 Государственное бюджетное образовательное учреждение высшего профессионального образования "Оренбургский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ОрГМУ Минздрава России) Средство для селективного влияния на биопленкообразование микроорганизмами
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
CN110448693A (zh) * 2019-07-30 2019-11-15 华东理工大学 氟喹诺酮类药物作为多粘菌素类抗生素增敏剂的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004438A (en) * 1991-12-31 1999-12-21 3M Innovative Properties Company Biofilm reduction sterilizer
TW385308B (en) * 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
TW533205B (en) * 1996-06-25 2003-05-21 Novartis Ag Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
AU3191597A (en) * 1996-06-26 1998-01-14 Sankyo Company Limited Novel medicinal compositions of hydropyridines
US6759040B1 (en) * 1997-09-12 2004-07-06 University Of Maryland, College Park Preparation and use of biofilm-degrading, multiple-specificity, hydrolytic enzyme mixtures
AU2001256965A1 (en) 2000-03-23 2001-10-03 Influx, Inc. Bactericidal antimicrobial methods and compositions for use in treating gram positive infections comprising an antibiotic potentiator having acyl hydrazide oxy amide or 8-hydroxy quinoline structure
AU2002254342A1 (en) * 2001-03-23 2002-10-08 The Board Of Trustees Of The University Of Illinois Compounds capable of modulating the activity of multidrug transporters and therapeutic use of the same
GB0126618D0 (en) * 2001-11-06 2002-01-02 Novartis Ag Organic compounds
GB0205593D0 (en) 2002-03-09 2002-04-24 Univ Nottingham Treatment of surfaces populated by bacteria
AU2003234670B2 (en) * 2002-05-24 2010-06-10 Angiotech International Ag Compositions and methods for coating medical implants
US7498292B2 (en) * 2002-08-15 2009-03-03 The Research Foundation Of State University Of New York Combinatorial libraries of autoinducer analogs, autoinducer agonists and antagonists, and methods of use thereof
GB0223978D0 (en) 2002-10-15 2002-11-20 Novartis Ag Organic compound
EP1994930A1 (fr) * 2007-05-22 2008-11-26 Novartis AG Compositions de triazole pour traiter la formation de biofilm

Also Published As

Publication number Publication date
TW200913996A (en) 2009-04-01
JP2010527960A (ja) 2010-08-19
RU2478385C2 (ru) 2013-04-10
EP2162130A1 (fr) 2010-03-17
CA2685112A1 (fr) 2008-11-27
JP5470245B2 (ja) 2014-04-16
WO2008142094A4 (fr) 2009-01-29
TN2009000487A1 (en) 2011-03-31
KR101519675B1 (ko) 2015-05-12
EP1994930A1 (fr) 2008-11-26
RU2009147297A (ru) 2011-06-27
ZA200907415B (en) 2010-07-28
IL201832A0 (en) 2010-06-16
US20120329746A1 (en) 2012-12-27
BRPI0811103A2 (pt) 2014-12-09
US8309590B2 (en) 2012-11-13
CL2008001469A1 (es) 2010-10-29
IL201832A (en) 2015-11-30
EP2253317A3 (fr) 2011-03-16
AU2008252964B2 (en) 2011-12-01
CN103381271A (zh) 2013-11-06
TWI419690B (zh) 2013-12-21
KR20100017153A (ko) 2010-02-16
US8592473B2 (en) 2013-11-26
WO2008142094A1 (fr) 2008-11-27
MX2009012628A (es) 2009-12-07
AU2008252964A1 (en) 2008-11-27
CN101678004A (zh) 2010-03-24
US20100152101A1 (en) 2010-06-17
EP2253317A2 (fr) 2010-11-24
NZ580735A (en) 2012-02-24

Similar Documents

Publication Publication Date Title
MA31388B1 (fr) Utilisation d'un composé i pour prévenir ou traiter une formation de biofilm
MA30932B1 (fr) Spirocetones servant d'inhibiteurs d'acetyl-coa -carboxylase
MA47368B1 (fr) N-[4-fluoro-5-[[(2s,4s)-2-méthyl-4-[(5-méthyl-1,2,4-oxadiazol-3-yl)méthoxy]-1-pipéridyl]méthyl]thiazol-2-yl]acétamide utilisés en tant qu'inhibiteur d'oga
MA30406B1 (fr) Nouveaux composes
MA38534A1 (fr) Compositions synergiques comprenant le (2s)-2-ethoxy-3-(4-(2-(2-methyl-5-(4-methylsulfanylphenyl)pyrrol-1-yl)ethoxy)phenyl)propanoate et des agents, par ex. Inhibiteurs de dipeptidyl peptidase-4, biguanide et/ou statines pour une utilisation dans la dyslipidémie
MA27751A1 (fr) 4-phényltétrahydroisoquinolines substituées, procédé de production de ces composés, utilisation de ces composés en tant que médicaments et médicament contenant de tels composés
MA31949B1 (fr) Dérivés d'aminotriazole comme agonistes d'alx
MA31894B1 (fr) Composes organiques
MA33636B1 (fr) Dérivés aminopropioniques substitués comme inhibiteurs de néprilysine
MA30999B1 (fr) Composés.
MA29213B1 (fr) Quinolones a substitution macrolones - amino
MA32798B1 (fr) Acides naphtylacétiques
TNSN00235A1 (fr) Derives d'heterocyclo-alkylsulfonylpyrazole nouveaux, procede pour leur preparation et compositions les contenant
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles
Laufer Discovery and development of ML3000
IL184116A0 (en) Use of thiazolidinone derivatives as antiangiogenic agents
RU2501791C2 (ru) Производное триазола или его соль
MA31130B1 (fr) Combinaison comprenant un chelatant du fer et un agent antineoplasique et ses applications
MA33166B1 (fr) Utilisation de dérivés de pyrimidylaminobenzamide pour le traitement de la fibrose
MA26741A1 (fr) Suspensions de ziprasidone nouvelles et procede pour leur preparation.
JP2008545627A5 (fr)
MA47082B1 (fr) Amides aromatiques d'acide carboxylique en tant qu'antagonistes des recepteurs bradykinin b1
MA30523B1 (fr) Compose tricylique et utilisation pharmaceutique de celui-ci
MA31902B1 (fr) Oxazolidinones pour le traitement et/ou la prophylaxie de l'insuffisance cardiaque
CA2461625A1 (fr) Irbesartan entrant dans la preparation des produits medicaux utiles pour prevenir ou traiter l'hypertension arterielle pulmonaire